Stock Analiz

ClearPoint Neuro, Inc. CLPT

Medical/Dental Instruments · data as of November 13, 2026

$8.48Market cap $272M
Open the interactive analysis →

ClearPoint Neuro, Inc. (CLPT) is a healthcare company listed in the US with a market value of about $272M. In the twelve months to September 30, 2026 it had revenue of $45M and net income of -$36M, a net margin of -79.4%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 24% a year, a 5-year average ROIC of -34%.

About ClearPoint Neuro

ClearPoint Neuro is listed in the US and classified in medical/dental instruments. Revenue went from $4M in 2014 to $37M in 2025, growth of about 23.6% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 17% over three years (dilution for shareholders). It spends 38% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth4/5
Track record1/5
Financial health0/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S6.0
P/B10.0
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-17.7%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)17.8%
Revenue growth (5 yrs, per year)23.6%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-78.0%
ROIC (5-yr avg.)-34.0%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$45M$37M$31M$24M$21M$16M$13M$11M$7M$7M$6M
Net income-$36M-$26M-$19M-$22M-$16M-$14M-$7M-$6M-$6M-$7M-$8M
Free cash flow-$48M-$24M-$9M-$14M-$16M-$13M-$8M-$3M-$5M-$6M-$6M
EPS (diluted)$-1.21$-0.90$-0.70$-0.90$-0.68$-0.69$-0.43$-0.42$-0.56$-0.93$-2.93
Net margin-79.4%-69.1%-60.2%-92.2%-80.0%-88.4%-52.9%-49.4%-83.8%-97.1%-140.4%
ROIC—-22.1%-53.8%-50.5%-26.4%-17.3%-18.5%-51.5%-83.1%-46.6%-158.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 2 analysts is $21.50, 154% above the current price; targets range from $18.00 to $25.00; the consensus rating is “none”; expected EPS is $-1.17 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does ClearPoint Neuro pay a dividend?

Not currently.

Is ClearPoint Neuro a good stock to buy?

We do not give buy or sell advice. ClearPoint Neuro scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.